Variable name;level;Overall;Grade I;Grade II;Grade III;p;test
;n;1357;58;528;760;;
Age;[0 -30);95;3 (3.2);34 (36.6);56 (60.2);<0.001;
;[30 -35);246;11 (4.5);69 (28);166 (67.5);;
;[35 -40);460;13 (2.9);176 (38.8);265 (58.4);;
;40+;554;31 (5.6);249 (45.1);272 (49.3);;
Number of children;0;373;11 (3);134 (36.3);224 (60.7);0.007;
;1;279;13 (4.7);92 (33);174 (62.4);;
;More than 1;705;34 (4.9);302 (43.3);362 (51.9);;
BMI;<18.5;79;3 (3.8);27 (34.2);49 (62);0.394;
;25-29.9;257;9 (3.5);97 (38);149 (58.4);;
;>=30;107;8 (7.6);42 (40);55 (52.4);;
;18.5-24.9;807;27 (3.4);324 (40.4);451 (56.2);;
Treatment center;Curie Paris;818;19 (2.3);310 (38.2);483 (59.5);<0.001;
;Curie St Cloud;538;39 (7.3);218 (40.8);277 (51.9);;
Hereditary predisposition;No;547;18 (3.3);184 (34);339 (62.7);0.052;
;Yes;140;4 (2.9);33 (23.6);103 (73.6);;
Inflammatory BC;No;1338;58 (4.4);521 (39.2);749 (56.4);0.652;
;Yes;18;0 (0);7 (38.9);11 (61.1);;
Clinical Tumor size (mm);;30.3 (21.7);25.0 (18.5);29.4 (21.5);31.4 (22.0);0.041;
Clinical N stage (TNM);N0;854;44 (5.2);332 (39.2);471 (55.6);0.550;
;N1;482;14 (2.9);188 (39.2);278 (57.9);;
;N2;7;0 (0);2 (28.6);5 (71.4);;
;N3;3;0 (0);1 (33.3);2 (66.7);;
Histological type;Lobular;54;3 (5.6);42 (77.8);9 (16.7);<0.001;
;NST;1265;54 (4.3);476 (37.8);729 (57.9);;
;Others;36;1 (3);10 (30.3);22 (66.7);;
Neoajuvant chemotherapy;No;744;47 (6.4);331 (45);358 (48.6);<0.001;
;Yes;612;11 (1.8);197 (32.3);402 (65.9);;
Chemotherapy setting;Adjuvant;744;47 (6.4);331 (45);358 (48.6);<0.001;
;Chemotherapy without surgery;1;0 (0);0 (0);1 (100);;
;NAC;611;11 (1.8);197 (32.3);401 (65.8);;
Fertility preservation discussion;No;909;42 (4.7);378 (41.9);482 (53.4);0.006;
;Yes;447;16 (3.6);150 (33.8);278 (62.6);;
